This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 7 of 100 for:    mdv3100 | Recruiting, Not yet recruiting, Available Studies

Effect of Enzalutamide Dose Reduction on Fatigue, Cognition, and Drug Trough Levels in Patients With Prostate Cancer (EFFECT)

This study is currently recruiting participants.
See Contacts and Locations
Verified April 2017 by Macquarie University, Australia
Sponsor:
Information provided by (Responsible Party):
Macquarie University, Australia
ClinicalTrials.gov Identifier:
NCT03124615
First received: April 13, 2017
Last updated: April 20, 2017
Last verified: April 2017
  Purpose

The primary purpose of this trial is to determine whether dose reduction of enzalutamide in patients with grade 3 fatigue and/or cognition change will lead to an improvement in symptoms while maintaining active drug levels.

Patients within 3 months of starting enzalutamide will be assessed by their oncologist as being potentially eligible for dose reduction due to the onset of moderate to severe fatigue and/or cognition change, which is assessed as being due to enzalutamide


Condition Intervention Phase
Prostate Cancer Drug: Enzalutamide Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Intervention Model Description:
Patients will have commenced standard dose enzalutamide (160mg) daily and dose will be reduced if Grade 3 fatigue or cognition change has occurred and if toxicity is attributed to enzalutamide
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effect of Enzalutamide Dose Reduction on Fatigue, Cognition, and Drug Trough Levels in Patients With Prostate Cancer

Resource links provided by NLM:


Further study details as provided by Macquarie University, Australia:

Primary Outcome Measures:
  • The proportion of patients who have an improvement in cognition/ fatigue symptoms [ Time Frame: 1 year post enrolment ]
    The primary endpoint is an improvement in the fatigue and cognition symptoms. Improvement will be de ned as the patient answering 'Better' in the cognition/ fatigue question at the lowest dose of enzalutamide.


Estimated Enrollment: 47
Anticipated Study Start Date: May 2017
Estimated Study Completion Date: June 2021
Estimated Primary Completion Date: December 2020 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Enzalutamide
Patients will have commenced standard dose enzalutamide (160mg) daily and dose will be reduced if Grade 3 fatigue or cognition change has occurred and if toxicity is attributed to enzalutamide
Drug: Enzalutamide
Enzalutamide is a FDA and Therapeutic Goods Administration (TGA, Regulatory Authority of therapeutic goods in Australia) approved treatment for castration resistant prostate cancer
Other Name: Xtandi

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Gender Eligibility Description:   The trial involves only the male population with prostate cancer
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Patients with prostate cancer who have commenced enzalutamide within 3 months
  2. Patient must have concomitant LHRH agonist or antagonist (no single agent enzalutamide)
  3. Receiving enzalutamide before or after docetaxel
  4. Patients may have hormone-sensitive or castrate resistant disease
  5. Patients may have metastatic (M1) or non-metastatic (M0) disease
  6. Onset of grade 3 or more cognition change and/or fatigue after commencement of enzalutamide considered to be due to enzalutamide

Exclusion Criteria:

  1. Clinical dementia
  2. Concomitant use of drugs known to impair cognition such as benzodiazepines or antihistamines.
  3. Concomitant use of strong CYP3A4 and/ or CYP2C8 inducers or inhibitors.
  4. Patient expected to have a change in opioid dose during the study period or have had a change 4 weeks before study entry.
  5. Diagnosed with sleep apnoea
  6. Brain metastases, prior seizures, drugs that significantly reduce seizure threshold.
  7. Active infection or other intercurrent illness that may contribute to fatigue or cognition change within 4 weeks of study entry.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT03124615

Contacts
Contact: Professor Gurney +61 2 9812 3526 clinicaltrials@mq.edu.au
Contact: Hung Tran +61 2 9812 3604 clinicaltrials@mq.edu.au

Locations
Australia, New South Wales
Macquarie University Recruiting
North Ryde, New South Wales, Australia, 2109
Contact: Hung Tran    +61 2 9812 3526    clinicaltrials@mq.edu.au   
Principal Investigator: Howard Gurney, MBBS         
Sponsors and Collaborators
Macquarie University, Australia
Investigators
Principal Investigator: Howard Gurney Medical Oncologist
  More Information

Responsible Party: Macquarie University, Australia
ClinicalTrials.gov Identifier: NCT03124615     History of Changes
Other Study ID Numbers: HGMQ201502
Study First Received: April 13, 2017
Last Updated: April 20, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No

Additional relevant MeSH terms:
Prostatic Neoplasms
Fatigue
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Genital Diseases, Male
Prostatic Diseases
Signs and Symptoms

ClinicalTrials.gov processed this record on September 19, 2017